Developmentally constrained plasticity as a therapeutic vulnerability in cancer

Cancer cells can exploit developmental lineage programs to generate phenotypic heterogeneity under therapeutic pressure. Although a subset of resistant tumors preserves its founding lineage, receptor, or oncogenic dependency, accumulating evidence shows that others enter reversible persister states or stabilize alternative lineage programs. Here we frame malignant plasticity as developmentally constrained, not limitless: cell of origin, lineage history, injury memory, genetic gates, chromatin state, transcription-factor circuits, and tumor-ecosystem feedback help delimit and probabilistically bias which state transitions are accessible under therapy. We distinguish physiological expansion of state space during repair from premalignant permissiveness and malignant fixation, and classify resistance into three modes: lineage-maintained resistance, adaptive reversible plasticity, and fixed reprogramming through lineage switching or histological transformation. These modes should be read as diagnoses rather than rigid therapeutic silos. Prime-then-kill strategies are most defensible when a resistant state is reversible, targetable, and paired with readouts; they may also be considered as biomarker-defined add-on hypotheses in lineage-maintained or lineage-rerouted disease when an evidence-supported state or immune-visibility module is present. Conversely, tumors that retain driver, receptor, or lineage dependency should keep the preserved axis or bypass pathway as the therapeutic backbone, and fixed histological transformation often requires treatment according to the new lineage. We also discuss how single-cell and spatial multi-omics can map state-space breadth and ecosystem context and, when paired with perturbational designs, help test transition capacity and reversibility; static marker expression alone cannot establish plasticity. A resistance-mode-guided approach can sharpen therapeutic hypotheses and limit overgeneralization across tumor types.